Please assess the completion status of the following clinical trial:

Trial Title: Pomalidomide, Dexamethasone and Rituximab in Waldenstrom's Macroglobulinemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* 18 years of age or older~* Able to adhere to the study visit schedule and other protocol requirements~* Clinicopathological diagnosis of Waldenstrom's macroglobulinemia using consensus panel criteria~* CD20 positive based on any previous performed bone marrow immunohistochemistry or flow cytometric analysis~* Meet criteria to treat based on consensus panel criteria~* Patient must have received at least one previous therapy for WM~* All previous cancer therapy, including radiation, hormonal therapy and surgery, must have been discontinued at least 4 weeks prior to treatment in this study~* Measurable disease, defined as presence of immunoglobulin M (IgM) paraprotein with a minimum IgM level of 2 times (or greater) the upper limit of each institution's normal value is required~* ECOG Performance status of 0, 1 or 2~* Laboratory tests within ranges outlined in the protocol~* Disease free of prior malignancies for 5 years or more with exception of currently treated basal cell, squamous cell carcinoma of the skin, or carcinoma in situ of the cervix or breast~* Screening of patients at high risk of HBV or HCV infection~* Willing and able to take aspirin or alternate prophylactic anticoagulants~Exclusion Criteria:~* Any serious medical condition, laboratory abnormality, or psychiatric illness~* Pregnant or lactating females~* Any condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study~* Resistance or intolerance to prior rituximab therapy~* Previous therapy with thalidomide or lenalidomide~* Known hypersensitivity to thalidomide, lenalidomide or pomalidomide~* The development of erythema nodosum if characterized by a desquamating rash while taking similar drugs~* Concurrent use of other anti-cancer agents or treatments~* History of non-compliance to medical regimens~* Patients unwilling to or unable to comply with the protocol~* Known positive for HIV or hepatitis infection~* Any history of CVA (Cerebral Vascular Accident/stroke) or clots~* Active DVT or PE that has not been therapeutically anticoagulated~* NYHA classification III and greater heart failure~* Any patient that is unable to ingest or process pomalidomide

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- pomalidomide, dexamethasone, rituximab (Type: EXPERIMENTAL): Drug: pomalidomide Taken orally once a day~Drug: dexamethasone Given intravenously on weeks 1, 2, 3 and 4 and weeks 12, 13, 14 and 15~Drug: rituximab Given intravenously on weeks 1, 2, 3 and 4 and weeks 12, 13, 14 and 15

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues